Home > Care & Treatment > Clinical Trials > Clinical Trials Search Results
The Young Women's Breast Cancer Study
For patients with 1-3 positive nodes, hormone receptor positive and HER2 negative breast cancer with recurrence score (RS) of 25 or less.
•Laboratory testing while in hospital •30 day clinic visit with laboratory testing •Telephone follow-up at 1 year
•Clinic visits during screening, randomization, week 1 and month 2 & every 6 months •Laboratory assessments at visits •participation is between 3 and 5 years
To help establish which treatments are effective in the treatment of Multiple Myeloma. This is a data registry and not a clinical trial that requires specific treatment regimes.
Phase II trial of combination Plerixafor (AMD3100), Bortezomib & Dexamethasone in relapsed or relapsed/refractory multiple myeloma.
Comparing conventional dose treatment using lenalidomide, bortezomib and dexamethasone (RVD) to high dose treatment with peripheral stem cell transplant.
A Phase II study of modified Lenalidomide, Bortezomib and Dexamethasone for transplant ineligible patients with newly diagnosed multiple myeloma.
A Phase II study of modified Lenalidomide, Bortezomib and Dexamethasone for Transplant Ineligible patients with newly diagnosed multiple myeloma.
Women > 65 years who are candidates for surgery
Cape Cod Hospital 27 Park Street Hyannis MA 02601 Phone: 508-771-1800 Directions
Falmouth Hospital 100 Ter Heun Drive Falmouth, MA 02540 Phone: 508-548-5300 Directions